Clinical Trial

Prostate Irreversible Electroporation Study

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Conventional treatment options for localized prostate cancer include prostatectomy, radiotherapy and active surveillance. However, prostatectomy and radiotherapy carry certain degree of morbidity, including the risks of urinary incontinence, erectile dysfunction and injury to the structures in the proximity. Active surveillance carries the risk of disease progression and psychological distress to the patients. Focal therapy employs the concept of only destroying the significant lesion, resulting in disease cure and improved functional outcome. Among the different options of focal therapy, Irreversible electroporation has evolved over the past decades and can be a reliable treatment option. Our study aims at assess the safety and effectiveness of such treatment in prostate cancer management.
Trial Details
NCT Number NCT06886321
Lead Sponsor Chinese University of Hong Kong
Conditions Prostate Cancer
Enrollment 10 participants
Start Date 2025-06-30
Primary Completion 2027-01-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-20